Strategic report Governance & remuneration Financial statements Investor information Notes to the company balance sheet UK GAAP including FRS 101 Reduced Disclosure Framework continued C Key accounting judgements and estimates Contingent consideration Any contingent consideration included in the consideration Legal and other disputes payable for a business combination is recorded at fair value at The company provides for anticipated settlement costs where the date of acquisition.
These fair values are generally based an outow of resources is considered probable and a reliable on risk-adjusted future cash ows discounted using appropriate estimate may be made of the likely outcome of the dispute and interest rates.
At 31 December 2015, the liability for contingent legal and other expenses arising from claims against the company.
consideration amounted to 405 million on the acquisition of the These estimates take into account the specic circumstances Vaccines business from Novartis in 2015. of each dispute and relevant external advice, are inherently judgmental and could change substantially over time as new facts The assumptions relating to future cash ows and discount rates emerge and each dispute progresses.
are based on business forecasts and are therefore inherently judgemental.
Future events could cause the assumptions used The companys Directors, having taken legal advice, have in these projections to change with a consequent adverse effect established provisions after taking into account the relevant facts on the future results of the company.
and circumstances of each matter and in accordance with accounting requirements.
At 31 December 2015 provisions for D Operating profit legal and other disputes amounted to 40 million 2014 A fee of 12,053 2014 11,523 relating to the audit of the 25 million.
company has been charged in operating profit.
The ultimate liability for legal claims may vary from the amounts E Dividends provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations.
The directors declared four interim dividends resulting in a The position could change over time and, therefore, there can be no dividend for the year of 80 pence, in line with the dividend for assurance that any losses that result from the outcome of any legal 2014.
A special dividend of 20 pence has also been declared in proceedings will not exceed the amount of the provisions reported the year.
For further details, see Note 16 to the Group financial in the companys financial statements by a material amount.
F Fixed assets investments 2015 2014 m m Shares in GlaxoSmithKline Services Unlimited 613 613 Shares in GlaxoSmithKline Holdings One Limited 18 18 Shares in GlaxoSmithKline Holdings Limited 17,888 17,888 Shares in GlaxoSmithKline Mercury Limited 33 33 18,552 18,552 Capital contribution relating to share based payments 1,139 1,139 Contribution relating to contingent consideration 405 20,096 19,691 G Trade and other receivables 2015 2014 m m Amounts due within one year: UK Corporation tax recoverable 201 205 Other receivables 41 3 Deferred tax recoverable 205 Amounts owed by Group undertakings 5,977 10,055 6,219 10,468 Amounts due after more than one year: Amounts due by Group undertakings 416 432 6,635 10,900 The deferred tax balance of 205 million reported in 2014 and reversed in 2015 arose as a result of the recognition of a deferred tax asset on tax losses expected to be used following completion of the Novartis transaction on 2 March 2015.
